Senate reform ushers in modern era for US FDA
This article was originally published in Clinica
For the second time in two years, the US Senate and Human Resources Committee has approved a bill that would modernise the work of the Food and Drug Administration. The measure was adopted on June 18 by a 14-4 vote with only a handful of minor amendments. Four Democrats sided with all 10 Republicans in supporting the legislation.
You may also be interested in...
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.